InSphero acquired cell-based assay services provider PhenoVista Biosciences to expand access to high-content imaging and phenotypic assay technologies and services. InSphero said the deal strengthens its assay portfolio across oncology and fibrosis and supports growth in neuroscience and neurotoxicity testing, while also expanding its US presence. Financial terms were not disclosed. PhenoVista has previously partnered with Carolina Molecular for orthogonal readouts, indicating the acquired capabilities may help integrate multi-modal discovery workflows into InSphero’s organ-on-a-chip and 3D assay ecosystem. For services and platform operators, the move signals consolidation around end-to-end phenotypic assay capacity and imaging-driven translational readouts as biotechs increasingly outsource complex assay development.